Bolt Biotherapeutics, Inc. Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
Bolt Biotherapeutics, Inc. is a biotechnology company based in the San Francisco Bay Area, with operations in Redwood City, California. It develops Boltbody ISACs, a class of immuno-oncology therapeutics that fuse immune-stimulating activity with antibodies targeting tumor antigens. In preclinical studies, systemic administration of these agents has produced tumor elimination and the generation of immunological memory, suggesting potential for durable clinical responses. The platform is described as broadly applicable across cancer types, including tumors that may resist current checkpoint inhibitors. The company was founded by Dr. Ed Engleman and is built on technology exclusively licensed from Stanford University. In April 2025, Bolt Biotherapeutics reported results from a Phase 1 dose-escalation study of BDC-3042 at the AACR Annual Meeting 2025.